Literature DB >> 30178793

A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents.

Nikunj B Bhatt1, Darpan N Pandya1, Stephanie Rideout-Danner2, Howard D Gage2, Frank C Marini3, Thaddeus J Wadas1.   

Abstract

Zirconium-89 is currently being used in numerous clinical trials involving monoclonal antibodies and positron emission tomography. This report describes a revised strategy that reduces preparation time while increasing the specific activity of clinically relevant immuno-PET agents. Additionally, it demonstrates that n-acetyl-l-cysteine acts as a superior radioprotective agent that improves long-term stability without compromising antigen affinity in vivo.

Entities:  

Year:  2018        PMID： 30178793      PMCID： PMC6192516          DOI： 10.1039/c8dt01841c

Source DB:  PubMed          Journal:  Dalton Trans        ISSN： 1477-9226            Impact factor:   4.390


  71 in total

1.  Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging.

Authors:  Eszter Boros; Jason P Holland; Nathaniel Kenton; Nicholas Rotile; Peter Caravan
Journal:  Chempluschem       Date:  2016-01-25       Impact factor: 2.863

2.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Authors:  Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

Review 3.  Discovery of PET radiopharmaceuticals at the academia-industry interface.

Authors:  Vadim Bernard-Gauthier; Thomas L Collier; Steven H Liang; Neil Vasdev
Journal:  Drug Discov Today Technol       Date:  2017-10-23

4.  Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.

Authors:  D L Kukis; G L DeNardo; S J DeNardo; G R Mirick; L A Miers; D P Greiner; C F Meares
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

Review 5.  Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab.

Authors:  Martín Granados-García; José Luis Aguilar-Ponce; Federico Maldonado-Magos; Jaime G De la Garza-Salazar
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2017-01-27       Impact factor: 1.538

6.  The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.

Authors:  O I Aruoma; B Halliwell; B M Hoey; J Butler
Journal:  Free Radic Biol Med       Date:  1989       Impact factor: 7.376

7.  Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.

Authors:  Wen Ping Li; Laura A Meyer; David A Capretto; Christopher D Sherman; Carolyn J Anderson
Journal:  Cancer Biother Radiopharm       Date:  2008-04       Impact factor: 3.099

8.  Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.

Authors:  Hugo J W L Aerts; Ludwig Dubois; Lars Perk; Peter Vermaelen; Guus A M S van Dongen; Bradly G Wouters; Philippe Lambin
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

9.  ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

Authors:  Andrew C Phillips; Erwin R Boghaert; Kedar S Vaidya; Michael J Mitten; Suzanne Norvell; Hugh D Falls; Peter J DeVries; Dong Cheng; Jonathan A Meulbroek; Fritz G Buchanan; Laura M McKay; Neal C Goodwin; Edward B Reilly
Journal:  Mol Cancer Ther       Date:  2016-02-04       Impact factor: 6.261

10.  Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.

Authors:  Aniek J G Even; Olga Hamming-Vrieze; Wouter van Elmpt; Véronique J L Winnepenninckx; Jolien Heukelom; Margot E T Tesselaar; Wouter V Vogel; Ann Hoeben; Catharina M L Zegers; Daniëlle J Vugts; Guus A M S van Dongen; Harry Bartelink; Felix M Mottaghy; Frank Hoebers; Philippe Lambin
Journal:  Oncotarget       Date:  2017-01-17
View more
  4 in total

1.  Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability.

Authors:  Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas
Journal:  Inorg Chem       Date:  2020-11-10       Impact factor: 5.165

2.  89Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo.

Authors:  Darpan N Pandya; Nikunj B Bhatt; Frankis Almaguel; Stephanie Rideout-Danner; Howard D Gage; Kiran Kumar Solingapuram Sai; Thaddeus J Wadas
Journal:  J Nucl Med       Date:  2018-11-15       Impact factor: 10.057

3.  A Systematic Evaluation of Antibody Modification and 89Zr-Radiolabeling for Optimized Immuno-PET.

Authors:  Sai Kiran Sharma; Jonathan M Glaser; Kimberly J Edwards; Elaheh Khozeimeh Sarbisheh; Akam K Salih; Jason S Lewis; Eric W Price
Journal:  Bioconjug Chem       Date:  2020-04-01       Impact factor: 6.069

4.  Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.

Authors:  Darpan N Pandya; Akesh Sinha; Hong Yuan; Lysette Mutkus; Kristina Stumpf; Frank C Marini; Thaddeus J Wadas
Journal:  Molecules       Date:  2020-08-12       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.